(Q35688173)

9 August 2017

1 reference

title

Initial antiretroviral therapy in chronically-infected HIV-positive adults (English)

1 reference

9 August 2017

Francesca Cainelli

2

0 references

Janak Koirala

object named as

Janak Koirala

4

0 references

author name string

Zelalem Temesgen

1

1 reference

9 August 2017

David Warnke

3

1 reference

9 August 2017

Collaborative Research Network (CORNET) Investigators

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

595-612

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.595

21 January 2018

Identifiers

DOI

10.1517/14656566.5.3.595

1 reference

9 August 2017

1 reference